Key result
Transcatheter pulmonary valve replacement has emerged as a viable alternative to surgical valve replacement for patients with right ventricular outflow tract dysfunction.
Why the study?
High surgical risk patients with repeat thoracotomies or comorbidities face perioperative events and prolonged hospitalization, highlighting the need to review PPVI indications, procedural details, and complications.
This review highlights the evolution, indications, and procedural aspects of transcatheter pulmonary valve replacement, emphasizing the necessity of a multidisciplinary heart team for managing high-risk and adult congenital heart disease patients.
Answers are grounded in this paper and cite their sources.
Transcatheter pulmonary valve therapies may lower risk in high-surgical-risk congenital patients; leaves open long-term durability data for native RVOT and valve-in-valve use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mike Saji (2020) conducted a review in Pulmonary valve stenosis and regurgitation, Adult congenital heart disease. Transcatheter Pulmonary Valve Replacement (TPVR) was evaluated. Transcatheter pulmonary valve replacement has emerged as a viable alternative to surgical valve replacement for patients with right ventricular outflow tract dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: